Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum

Reuters09-15

Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral <a href="https://laohu8.com/S/LICN">Lichen</a> Planus at Upcoming Life Sciences Virtual Investor Forum

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH73021) on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567111928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567111928","market":"fut","top_or_hot":-1,"title":"Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral <a href=\"https://laohu8.com/S/LICN\">Lichen</a> Planus at Upcoming Life Sciences Virtual Investor Forum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LIPO\">Lipella Pharmaceuticals Inc</a>., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH73021) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral <a href=\"https://laohu8.com/S/LICN\">Lichen</a> Planus at Upcoming Life Sciences Virtual Investor Forum\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LIPO\">Lipella Pharmaceuticals Inc</a>., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH73021) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIPO","symbol_name":"Lipella Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL3kXJQQ:1","article_id":"2567111928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567111928","pubTimestamp":1757937715,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum. Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIPO":"Lipella Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"Lipella Pharmaceuticals将在即将举行的生命科学虚拟投资者论坛上展示LP-10治疗口腔扁平苔藓的最终2a期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIPO":0.9},"content_text":"Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum\n    \n\nLipella Pharmaceuticals Inc., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH73021) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567111928","isCrawlerRequest":true}